Adelene Perkins

Chair and Chief Executive Officer

Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Before serving as CEO, Ms. Perkins served as Infinity’s President, a position she held since 2008. Ms. Perkins joined Infinity in June 2002 as executive vice president and chief business officer.

Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the co-founder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University.  She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.

Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is the vice chairman of the Board of Project Hope. She is a past member of the Boards of Padlock Therapeutics, prior to its acquisition by Bristol-Myers Squibb, and the Massachusetts Life Science Center.

Lawrence Bloch, M.D., J.D.

President

Lawrence Bloch, M.D., J.D. is president of Infinity. He joined the company as chief financial officer and chief business officer in 2012 and has played a key role in developing and executing the company’s corporate and financial strategies. Prior to joining Infinity in 2012, Dr. Bloch served as chief executive officer of NeurAxon, Inc., a company focused on developing next-generation pain therapeutics, from 2007 to 2011. Previously, he served as chief business officer and chief financial officer of NitroMed, Inc., raising $150 million in equity and $20 million in venture debt to support the commercial launch of BiDil®. From 1999 to 2004, he served as chief financial officer and vice president of business development of Applied Molecular Evolution, Inc., leading the company’s $101 million initial public offering and $420 million merger with Eli Lilly and Company.

Dr. Bloch began his career as an emergency medicine resident physician at Massachusetts General Hospital and Brigham & Women’s Hospital. He holds a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an MBA from Harvard Business School.

Robert Ilaria, Jr., M.D.

Chief Medical Officer

Robert Ilaria, Jr., M.D. serves as Chief Medical Officer at Infinity.  Dr. Ilaria joined Infinity from Bristol Myers Squibb and Celgene, where he focused on immuno-oncology drug development, serving leadership roles on the CTLA-4 and PD-1 inhibitor drug development teams, respectively.  Prior to joining Celgene, Dr. Ilaria was at Eli Lilly from 2005-2017 in leadership roles of increasing responsibility in both Early and Late Phase drug development.  During his time at Eli Lilly, Dr. Ilaria was responsible for the clinical strategy of multiple assets ranging from pre-clinical development through regulatory approval.

Prior to joining the pharmaceutical industry, Dr. Ilaria had academic clinical and basic science research careers at UT Southwestern and Harvard Medical School.  He holds a BA in biology and philosophy from Rice University and an MD from UT Southwestern Medical School.  He did his internal medicine and hematology and medical oncology training at Brigham and Women’s Hospital and the Dana Farber Cancer Institute.   Dr. Ilaria has remained clinically active during his pharmaceutical career through volunteer oncology staff service at academic teaching institutions.

Seth Tasker

Chief Business Officer

Seth Tasker is Chief Business Officer of Infinity with responsibility for business development, legal affairs, human resources and information technology functions. Mr. Tasker has more than 17 years of experience in the pharmaceutical industry and brings expertise in corporate finance and partnering transactions, corporate governance, securities, compliance, employment law and other legal and operational issues relevant to developing new medicines in both the private and public company setting. Prior to joining Infinity in 2008, Mr.Tasker served as associate counsel at Surface Logix, Inc., a privately held biotechnology company focused on developing improved drug therapies addressing Type 2 diabetes, cardiovascular health and oncology. Mr. Tasker received a J.D. and M.B.A from Suffolk University and a B.S. in microbiology from the University of Vermont.

Stéphane Peluso, Ph.D.

Chief Scientific Officer

Stéphane Peluso, Ph.D., is Chief Scientific Officer of Infinity. Dr. Peluso returns to Infinity from Ipsen Bioscience where he was most recently Vice President, Global Head of Oncology External Innovation. Prior to Ipsen, Dr. Peluso worked at Infinity where he held positions of increasing responsibility in medicinal chemistry and drug discovery ultimately leading Infinity’s early discovery and pipeline expansion efforts through both internal R&D and business development. Dr. Peluso started his career as a medicinal chemist at Millennium Pharmaceuticals. He graduated from the Ecole Supérieure de Chimie Industrielle de Lyon (ESCIL), France, obtained his Ph.D. from the University of Lausanne, Switzerland and completed postdoctoral studies at the Massachusetts Institute of Technology.